In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...
AbbVie's Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the non-segmental ...
Analysts at GlobalData forecast that GCG/GLP-1RA mazdutide will become a blockbuster seller in China for Innovent by 2030.
The company’s stock rose significantly after it announced the full Phase I/II data. Image credit: Lightspring / Shutterstock.com. Intensity Therapeutics’ stock has risen nearly 400% after its oncology ...
Aditya Kotta discussed the biotech funding environment and market trends at OCTSC meeting, in San Diego, California, US. Credits: Athanasios Psimadis / Arena International. The biotech sector has ...
The app helps sites and patients stay synchronised, supporting compliance. Credit: SOMKID THONGDEE/Shutterstock.com. US-based software company Suvoda has launched a unified patient mobile app to ease ...
Zenas BioPharma’s investigational relapsing multiple sclerosis (RMS) asset, obexelimab, has met its primary endpoint in the Phase II MoonStone trial. Image credit: OksanaFedorchuk via Shutterstock.com ...
The double-blind, randomised, vehicle-controlled study enrolled 241 patients. Credit: TY Lim / Shutterstock.com. Incyte has announced results from the Phase IIIb TRuE-AD4 trial of Opzelura ...
BridgeBio’s stock was up after it announced the Phase III trial met its endpoints. Image credit: saepul_bahri / Shutterstock.com. BridgeBio Pharma will seek US approval of its limb-girdle muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback